Full HAELO Phase 3 results presented at EAACI 2026 and published in NEJM

Intellia Therapeutics/Lonvo-z (NTLA-2002)

The full HAELO Phase 3 results for Intellia's lonvo-z were presented at the EAACI 2026 conference and published in the New England Journal of Medicine, confirming that a single 50 mg infusion that inactivates the KLKB1 gene in the liver reduced hereditary angioedema attack rates by 87 percent compared with placebo over six months.

• 80-patient Phase 3 trial; single 50 mg infusion reduced attacks 87% versus placebo
• Mean monthly attack rate 0.26 on lonvo-z versus 2.10 on placebo
• 62% of treated patients were entirely attack-free and therapy-free for six-month period versus 11% placebo
• All adverse events mild to moderate; no serious events in lonvo-z group; rolling BLA initiated